推荐产品
生物源
human
品質等級
重組細胞
expressed in HEK 293 cells
化驗
≥95% (SDS-PAGE)
形狀
lyophilized powder
效力
≤5.0 ng/mL ED50
品質
endotoxin tested
分子量
dimer 36 kDa (glycosylated)
包裝
pkg of 10 μg
儲存條件
avoid repeated freeze/thaw cycles
技術
cell culture | mammalian: suitable
雜質
≤1 EU/μg
UniProt登錄號
儲存溫度
−20°C
基因資訊
human ... EPO(2056)
正在寻找类似产品? 访问 产品对比指南
一般說明
EPO has been cloned from various species including human, murine, canine, and others. The mature proteins from the various species are highly conserved and exhibit greater than 80% amino acid sequence identity. EPO contains three N-linked glycosylation sites. The glycosylation of erythropoietin is required for the biological activities of erythropoietin in vivo.
生化/生理作用
Erythropoietin is a glycoprotein that is the principal regulator of red blood cell growth and differentiation.
Erythropoietin (EPO), produced primarily by the kidney, is the primary regulatory factor of erythropoiesis. It promotes the proliferation, differentiation, and survival of the erythroid progenitors. Erythropoietin stimulates erythropoiesis by inducing growth and differentiation of burst forming units and colony forming units into mature red blood cells. EPO produced by kidney cells is increased in response to hypoxia or anemia. The biological effects of erythropoietin are mediated by the erythropoietin receptor, which binds EPO with high affinity and is a potent EPO antagonist.
準備報告
Human EPO is expressed as a glycosylated 36 kDa monomer in human HEK 293 cells. Production in human HEK 293 cells offers authentic glycosylation. Glycosylation contributes to stability in cell growth media and other applications.
分析報告
The specific activity was determined by the dose-dependent stimulation of the proliferation of human TF-1 cells (human erythroleukemic indicator cell line).
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 2
閃點(°F)
Not applicable
閃點(°C)
Not applicable
其他客户在看
Nature medicine, 20(4), 408-414 (2014-03-25)
Erythropoietin (EPO) stimulates proliferation of early-stage erythrocyte precursors and is widely used for the treatment of chronic anemia. However, several types of EPO-resistant anemia are characterized by defects in late-stage erythropoiesis, which is EPO independent. Here we investigated regulation of
Anesthesiology, 120(4), 839-851 (2014-01-16)
Patient blood management combines the use of several transfusion alternatives. Integrated use of erythropoietin, cell saver, and/or postoperative drain reinfusion devices on allogeneic erythrocyte use was evaluated using a restrictive transfusion threshold. In a factorial design, adult elective hip- and
Cardiovascular drugs and therapy, 27(4), 315-331 (2013-05-23)
Erythropoietin (EPO) is the main hormone that regulates erythropoiesis. Beyond its well-known hematopoietic action, EPO has diverse cellular effects in non-hematopoietic tissues. It has been shown to inhibit apoptosis by activating pro-survival pathways in the myocardium, to mobilize endothelial progenitor
JAMA, 312(8), 817-824 (2014-08-27)
Premature infants are at risk of developing encephalopathy of prematurity, which is associated with long-term neurodevelopmental delay. Erythropoietin was shown to be neuroprotective in experimental and retrospective clinical studies. To determine if there is an association between early high-dose recombinant
Cold Spring Harbor perspectives in medicine, 3(3), a011619-a011619 (2013-03-05)
During the past century, few proteins have matched erythropoietin (Epo) in capturing the imagination of physiologists, molecular biologists, and, more recently, physicians and patients. Its appeal rests on its commanding role as the premier erythroid cytokine, the elegant mechanism underlying
商品
Read article on hematopoietic cytokines and hematopoiesis
Read article on hematopoietic cytokines and hematopoiesis
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门